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Methylation of cell-free circulating
DNA in the diagnosis of cancer
Kristina Warton and Goli Samimi *
Garvan Institute of Medical Research, The Kinghorn Cancer Centre and St Vincent’s Clinical School, University of New South
Wales, Sydney, NSW, Australia
A range of molecular alterations found in tumor cells, such as DNA mutations and
DNA methylation, is reflected in cell-free circulating DNA (circDNA) released from the
tumor into the blood, thereby making circDNA an ideal candidate for the basis of a
blood-based cancer diagnosis test. In many cancer types, mutations driving tumor
development and progression are present in a wide range of oncogenes and tumor
suppressor genes. However, even when a gene is consistently mutated in a particular
cancer, the mutations can be spread over very large regions of its sequence, making
evaluation difficult. This diversity of sequence changes in tumor DNA presents a challenge
for the development of blood tests based on DNA mutations for cancer diagnosis.
Unlike mutations, DNA methylation that can be consistently measured, as it tends to
occur in specific regions of the DNA called CpG islands. Since DNA methylation is
reflected within circDNA, detection of tumor-specific DNA methylation in patient plasma
is a feasible approach for the development of a blood-based test. Aberrant circDNA
methylation has been described in most cancer types and is actively being investigated
for clinical applications. A commercial blood test for colorectal cancer based on the
methylation of the SEPT9 promoter region in circDNA is under review for approval by
the Federal Drug Administration (FDA) for clinical use. In this paper, we review the state
of research in circDNA methylation as an application for blood-based diagnostic tests in
colorectal, breast, lung, pancreatic and ovarian cancers, and we consider some of the
future directions and challenges in this field. There are a number of potential circDNA
biomarkers currently under investigation, and experience with SEPT9 shows that the
time to clinical translation can be relatively rapid, supporting the promise of circDNA as
a biomarker.
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DNA Methylation as a Biomarker
One of the surprising aspects of cancer biology that emerged from The Cancer Genome Atlas
(TCGA) sequencing projects was the wide diversity of mutations that give rise to cancer (Vogel-
stein et al., 2013). Even within a single tumor type the mutation profiles vary from patient to
patient, and it’s not unusual for even the most commonly altered genes to be mutated in less than
half of the cases. For example, TCGA sequencing of breast cancer showed that the two most com-
monly mutated genes, TP53 and PIK3CA, are only mutated in 37 and 36% of tumors, respectively
(Cancer Genome Atlas, 2012). The mutation frequency then drops off sharply, with most of
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the remaining top 23 genes mutated in <5% of tumors. Even
when a single gene is commonly mutated in a particular cancer
type, the sequence changes can be spread over large stretches of
DNA. For example, TP53 is one of the most consistently altered
genes in high grade serous ovarian cancer (HGSOC), with around
95% of tumors harboring a mutation (Ahmed et al., 2010; Cancer
Genome Atlas Research Network, 2011). However, as predicted
for a tumor suppressor gene (Vogelstein et al., 2013), the muta-
tions show minimal clustering and are spread over several exons
(Hollstein et al., 1991; Cancer Genome Atlas Research Network,
2011), which span nearly 20 kilobases of sequence. The TCGA
ovarian cancer sequencing project identified seven other signif-
icantly mutated genes, but these were only present in 2–6% of
samples (Cancer Genome Atlas Research Network, 2011). This
diversity of mutations provides a challenge for the development
of cancer diagnosis tests based on DNA sequence changes, as very
large proportions of the genome would need to be interrogated to
provide a test of adequate sensitivity (Schmidt and Diehl, 2007).
The variability of cancer mutation profiles contrasts with the
stability of CpG island methylation changes. The 14-3-3 sigma
promoter has been found to be methylated in 96% of breast car-
cinomas, and unmethylated in the breast epithelium of individ-
uals without cancer (Umbricht et al., 2001). While not a good
candidate biomarker for a breast cancer blood test, since 14-3-3
sigma is also heavily methylated in leukocytes (Umbricht et al.,
2001), this level of methylation underlies the homogeneity of
certain DNA methylation changes as compared with mutations.
Along the same lines, the HOXA9 promoter and EN1 promoter
were found to be methylated in 95 and 80% of HGSOC ovarian
cancers, respectively (Montavon et al., 2012). Given the greater
consistency of DNA methylation changes in cancer compared
to mutations, methylation is a promising target for biomarker
development.
Cell-Free Circulating Plasma DNA
Cell-free circulating plasma DNA (circDNA) is DNA found in
blood plasma which is not associated with any cell fraction. cir-
cDNA is generally shed from normal cells, including leukocytes.
In individuals with cancer a proportion of circDNA is derived
from tumor cells, and not only contains the same mutations as
tumor cells, but also the same methylation pattern (Schwarzen-
bach et al., 2011). Furthermore, studies have demonstrated that
circDNA can be detected in most patients harboring solid tumors
with advanced disease, as well as in a lower fraction of patients
with localized disease (Bettegowda et al., 2014). Thus, tumor-
specificmethylation in circDNA is a potential target for the devel-
opment of non-invasive, blood-based assays for cancer diagnosis
(Supplementary Table 1).
circDNA has been extracted from both plasma and serum.
Serum typically yields higher amounts of DNA (Lo et al., 1998;
Lee et al., 2001; Lui et al., 2002; Jung et al., 2003; Warton et al.,
2014); however, there is evidence that the additional DNA seen
in serum is in fact derived from leukocytes which lyse during
serum processing, rather than a reflection of greater amounts
of circDNA (Lee et al., 2001; Warton et al., 2014). Supporting
this notion, serum from female blood spiked with male-derived
leukocytes prior to isolation contains Y-chromosome sequences,
indicating that leukocytes are subject to lysis during the clot-
ting process (Lee et al., 2001). As an alternate hypothesis, the
higher circDNA concentration in serum has been postulated to
be due to chemical differences between plasma and serum which
render serum more amenable to DNA extraction. However, lev-
els of serum circDNA have been shown to rise with even short
(2–8 h) increases in clotting times, during which serum chem-
istry is not likely to change (Jung et al., 2003; Warton et al., 2014).
Instead the observation of increased yield with prolonged clot-
ting is consistent with ongoing leukocyte lysis. Serum may still
prove a valuable source of biomarkers if the biomarker chosen is
not compromised by an increased level of background leukocyte
DNA, or even if it itself is derived from lysed leukocytes. How-
ever, to avoid clouding the issue we have chosen to focus this
review on plasma, which we believe is less likely to be impacted
by sample processing artifacts.
Colorectal Cancer
Colorectal cancer is the 3rd most common diagnosed cancer and
cause of cancer-related death in both men and women (Siegel
et al., 2014). Tests for the presence of colorectal cancer in the
form of sigmoidoscopy/colonoscopy and the fecal occult blood
test (FOBT) have existed for over 50 years and are an illus-
trative example of the potential of screening to reduce can-
cer mortality, with several large, long-term follow-up studies
demonstrating the benefit of screening. The Minnesota Colon
Cancer Control Study showed a relative risk of 0.68 (95%CI 0.56–
0.82) among participants randomized to annual FOBT screen-
ing compared to the control group over 30 years of follow-up
(Shaukat et al., 2013). The Nurses’ Health Study (Nishihara
et al., 2013) and the Nottingham trial (Scholefield et al., 2012)
also showed reductions in colorectal cancer mortality following
colonoscopy/sigmoidoscopy and FOBT screening, respectively;
however, screening compliance in the Nottingham trial was only
around 60%, highlighting a potential area for improvement for
existing tests.
New screening tests for colorectal cancer seek improvements
in sensitivity and specificity of the diagnosis, but also alterna-
tive formats to fecal screening or colonoscopy, which have been
shown to have low uptake in a population screening setting
(Scholefield et al., 2012). The septin 9 (SEPT9) gene promoter
region was initially identified as being differentially methylated
in a discovery project comparing colorectal tumors, healthy
adjacent tissues, peripheral blood lymphocytes, and other non-
colonic, non-pathologic control tissues which could hypotheti-
cally contribute DNA to plasma (Lofton-Day et al., 2008). As the
biomarker was intended specifically for development into a blood
test, there was a stringent requirement at the discovery phase that
it shows minimal or absent levels of methylation in leukocytes.
Following identification as a potential biomarker, SEPT9 was
evaluated in retrospective trials comparing plasma methylation
in people diagnosed with colorectal cancer and healthy controls
(Grutzmann et al., 2008; Devos et al., 2009; Warren et al., 2011).
When these gave promising results, ranging between 72–90% for
sensitivity and 88–90% for specificity, a large scale, multicentre
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prospective study, the PRESEPT trial, was undertaken (Church
et al., 2014). This trial enrolled over 7900 participants from
among patients scheduled for colonoscopy, 53 of whom were
on examination found to have colorectal cancer. In the trial the
SEPT9 methylation assay showed a disappointing 48.2% sensi-
tivity for detecting pre-clinical colorectal cancer, with a 91.5%
specificity. A suggested reason why this prospective trial did not
perform as well as the retrospective study is that the retrospec-
tively collected samples were from cases diagnosed symptomat-
ically rather than in a screening setting, and these may have
differed from asymptomatic screen-detected cases. However, in
the course of the PRESEPT trial a simple technical change to the
assay, designating a patient sample as positive when 1 of 3 rather
than 1 of 2 PCR reactions showed methylated SEPT9 amplifica-
tion, was identified as giving better sensitivity and incorporated
into the trial. This resulted in a sensitivity 63.9% and a speci-
ficity of 88.4% (Warren et al., 2011; Church et al., 2014). The
effect of this modification is yet to be prospectively evaluated in a
large scale, multicentre trial; however, a de-novo re-testing of the
PRESEPT participant samples appears encouraging (Potter et al.,
2014).
While other diagnostic modalities may perform better than
the methylated SEPT9 test at the assay level (Ahlquist et al.,
2012; Ladabaum et al., 2013), low testing uptake has been con-
sistently identified as a problem in colorectal cancer screen-
ing, and insofar as the SEPT9 test can overcome this it
is adequately sensitive to provide patient benefit as well as
cost effective (Ladabaum et al., 2013). The SEPT9 test also
has potential for further technical improvement, for exam-
ple, the PCR reaction on which the test is based appears
sensitive to blood derived inhibitors which are responsible
for a proportion of the false negative results (Grutzmann
et al., 2008) and, despite some effort in this direction, these
inhibitors are yet to be identified (Potter et al., 2014). Over-
all, the SEPT9 test is a very encouraging example of bringing a
methylation-based blood biomarker from the laboratory to the
clinic.
Other methylation-based plasma biomarkers that differenti-
ate control blood samples and samples from patients with col-
orectal cancer have been identified, both through whole genome
screening (Lange et al., 2012; Pedersen et al., 2014; Takane et al.,
2014) as well as through candidate gene testing (Lee et al., 2009;
Cassinotti et al., 2011; Danese et al., 2013; Pack et al., 2013;
Melotte et al., 2015) approaches. These include the promoters
of genes which have a well-established role in cancer progres-
sion such as RASSF1A, APC and E-cadherin (Cassinotti et al.,
2011; Pack et al., 2013), as well as completely novel sequences
such as CAHM, a long non-coding RNA gene (Pedersen et al.,
2014). In these initial studies some of the methylated sequences
showed sensitivity and specificity that compare well to early
results obtained with SEPT9; for example, the promoter region
of THBD was able to differentiate colorectal cancer and control
blood samples with a sensitivity of 71% and a specificity of 80%
(Lange et al., 2012). However, the newmarkers described have yet
to be evaluated in independent studies, either retrospectively or
prospectively, which would give a clearer idea of their potential
clinical utility.
Breast Cancer
As with colorectal cancer, non-blood-based screening tests for
breast cancer are already in clinical use. Mammography and
ultrasound can reveal suspicious tissue lesions, and these can be
followed up by fine needle biopsy if necessary. However, the sen-
sitivity and specificity of these tests are only moderate and vary
greatly (Drukteinis et al., 2013), and patient benefits of popula-
tion screening can be difficult to detect, even with very large, well-
powered clinical trials (Independent UK Panel on Breast Cancer
Screening, 2012). Concerns regarding existing tests are that over-
diagnosis leads to unnecessary surgery on lesions that would not
have progressed further, while many malignant tumors remain
undetected (Independent UK Panel on Breast Cancer Screening,
2012). Hence the hope is that a blood test would improve on the
sensitivity and specificity of current screening.
A number of potential methylation biomarkers that differen-
tiate control plasma and plasma from patients with breast can-
cer have been found, mostly using the candidate gene approach
(Hoque et al., 2006; Skvortsova et al., 2006; Ng et al., 2011; Rad-
pour et al., 2011; Chimonidou et al., 2013a,b; Guerrero-Preston
et al., 2014). As such, the regions identified lie in the promot-
ers of genes already well-defined as having a role in cancer, for
example RASSF1A (Hoque et al., 2006; Skvortsova et al., 2006),
APC (Hoque et al., 2006; Radpour et al., 2011) and SOX17 (Chi-
monidou et al., 2013a). Notably, CST6 has been identified by two
independent groups as being differentially methylated between
breast cancer and control plasma samples (Radpour et al., 2011;
Chimonidou et al., 2013b). Chimonidou et al. (2013b) used bisul-
phite conversion and methylation-specific PCR of circDNA to
show that the CST6 promoter was methylated in two sepa-
rate cohorts of breast cancer patients, with methylation found
in 14/73 patients (19.2%) in the first cohort, and in 49/123
patients (39.8%) in the second cohort, while none of the 37
healthy individuals tested showed methylation. One caveat of
this study is that the plasma samples were collected 2–4 weeks
after surgery, and a decrease in tumor-derived circDNA follow-
ing tumor removal is well-documented (Diehl et al., 2008; Li et al.,
2009).
The highest sensitivity and specificity for detection was
obtained using an 8-gene biomarker panel (that included CST6),
which correctly identified 91.7% of cancer samples, and 90% of
cancer negative samples in a retrospective cohort consisting of
36 patients mostly with early stage breast cancer, and 30 healthy
controls (Radpour et al., 2011). However, this study also showed
an identifiable level of CST6 methylation in the control samples
(Radpour et al., 2011).
To our knowledge, to date there have only been reports
presenting the first description of potential methylation
biomarker(s) in breast cancer using relatively small sample
numbers, and these have not as yet been followed up by indepen-
dent larger studies, either prospective or retrospective. It is also
not known whether the most appropriate biomarkers differ by
breast cancer subtype. So far biomarker discovery studies have
generally been performed on mixed cohorts of ER-positive and
ER-negative patients, potentially further decreasing the power of
the trials.
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Lung Cancer
Despite recent decreases in smoking in developed nations, the
lag time between carcinogen exposure and the development of
tumors means that lung cancer continues to be responsible for
the biggest fraction of cancer mortality among both men and
women (Siegel et al., 2014). Methylated CDKN2A (often des-
ignated as p16) was an early focus of the search for a plasma
diagnostic biomarker for lung cancer; however, while the early
studies identified CDKN2A promoter methylation in the plasma
of lung cancer patients, they either had very small numbers of
healthy controls (Bearzatto et al., 2002), or they did not include
a cancer-free control group in their analysis (Kurakawa et al.,
2001; An et al., 2002; Ng et al., 2002), extrapolating instead
from the lack of CDKN2A methylation in plasma of patients
whose tumors were CDKN2Amethylation free. Subsequent stud-
ies found CDKN2A methylation in the plasma of 7/74 (9%),
3/33 (9%), and 4/50 (8%) of cancer-free controls (Belinsky et al.,
2005; Hsu et al., 2007; Zhang et al., 2011), while methylation
among patients with cancer included values of 25/110 (22%),
21/55 (38%), and 61% sensitivity (Wang et al., 2006; Hsu et al.,
2007; Zhang et al., 2011). These numbers suggest that if methy-
lated plasma CDKN2A is to be useful in detecting lung cancer, it
will likely be as part of a biomarker panel rather than as a single
gene.
Other promoters which were found by independent studies
to be differentially methylated in circDNA between patients with
cancer and cancer free controls include APC (Usadel et al., 2002;
Rykova et al., 2004; Zhang et al., 2011), RASSF1A (Rykova et al.,
2004; Belinsky et al., 2005; Wang et al., 2006; Hsu et al., 2007;
Ponomaryova et al., 2011; Zhang et al., 2011), RARb (Rykova
et al., 2004; Wang et al., 2006; Hsu et al., 2007; Ostrow et al.,
2010; Ponomaryova et al., 2013), andCDH13 (Rykova et al., 2004;
Wang et al., 2006; Hsu et al., 2007; Zhang et al., 2011); however,
the sensitivities were generally low. A relatively well-powered,
retrospective study by researchers from the diagnostic firm Ther-
acode identified SHOX2 as a potential biomarker (Kneip et al.,
2011). An initial training set of 20 lung cancer cases and 20 con-
trols was used to establish an assay cutoff value, and then a total
of 371 cancer and control samples were tested and found a sensi-
tivity of 60% (CI 53–67%) and a specificity of 90% (CI 84–94%)
(Kneip et al., 2011). Finally, the SEPT9methylation test originally
developed for plasma detection of colorectal cancer has been
applied to lung cancer, and correctly identified 31/70 (44%) of
lung cancer samples, while only giving a positive signal in 4/100
controls (Powrozek et al., 2014).
The development of a lung cancer biomarker presents par-
ticular problems in the choice of an appropriate control group.
In the majority of cases lung cancer is linked to smoking, and
smoking itself leads to gene methylation changes (Ostrow et al.,
2013). Hence smokers with no evidence of lung cancer are a good
control group, as this approach would avoid selection of methyla-
tion markers which simply identify people who smoke. However,
some of the potential circDNA methylation biomarkers exam-
ined have been found to have differences in specificity, i.e., the
ability to correctly identify negative samples, between smoker
and non-smoker controls (Ostrow et al., 2010). Without lengthy
follow-up of the negative control subjects, it is not clear whether
these signals in the smoker group are false positives, or detec-
tion of early events in the initiation of lung cancer (Ostrow et al.,
2010).
Pancreatic Cancer
Pancreatic cancer is one of the most lethal cancers in men and
women (Siegel et al., 2014). Late detection of tumors due to few
symptoms at early stages means that, by the time the cancer
has been diagnosed, it has spread such that it cannot be surgi-
cally removed. As with other cancers, earlier detection improves
patient outcomes. Compared to patients with advanced tumors,
patients with tumors ≤1 cm at surgery appear to do relatively
well, with>70% 5-year survival (Ishikawa et al., 1999). The small
size of the target lesion is cited as one of the reasons for the dif-
ficulty of early pancreatic cancer detection, as tumors of this size
are considered unlikely to shed large amounts of DNA into the
blood (Lennon et al., 2014).
A recent study by Nones et al. (2014), as part of the Australian
Pancreatic Cancer Genome Initiative (APGI), found high levels
of aberrant methylation in crucial signaling pathways, suggesting
its feasibility as a biomarker for disease. With regards to plasma
methylated biomarker discovery, the pancreatic cancer field is
still in early stages, and the number of studies carried out to date
is small. One of the first studies identified PENK and CDKN2A
methylation in the plasma of 21.4 and 45.4% of patients with
localized pancreatic cancer, however, this study did not include
a cancer-free control group (Jiao et al., 2007). Using a panel of 6
candidate genes, UCHL1, NPTX2, SARP2, ppENK, CDKN2A and
RASSF1A, Park showed that while all gene promoters were differ-
entially methylated between patients with pancreatic cancer and
healthy controls, only one gene promoter, CDKN2A, was differ-
entially methylated between patients with pancreatic cancer and
those with chronic pancreatitis, a known risk factor for pancreatic
cancer (Park et al., 2012).
One discovery technique involves a microarray test panel
of 56 frequently methylated genes that is used to measure the
quantity of methylated target sequence following digestion with
the methylation sensitive endonuclease Hin6I, and PCR ampli-
fication of undigested (i.e., methylated) fragments (MethDet56)
(Melnikov et al., 2009b). This technique has been used to iden-
tify promoters that are hypomethylated in the plasma of pancre-
atic cancer patients relative to controls. CCND2, SOCS1, THBS,
PLAU, and VHL were identified as being unmethylated in can-
cer samples relative to healthy controls (Melnikov et al., 2009b).
However, the application of a biomarker based on decreased
methylation is problematic. While shedding of hypomethylated
tumor DNA into the bloodstream may lead to a decrease in the
circDNA methylation signal, tumor DNA would have to form a
large proportion of circDNA for this decrease to be detectable.
It is unlikely that the tiny amounts of tumor DNA introduced
into the bloodstream from early stage cancers would result in a
detectable decrease in DNAmethylation. On the other hand, lack
of detectable methylation is potentially useful in distinguishing
cancer from conditions which present with similar symptoms.
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TheMethDet56method described above was used to differentiate
between healthy controls, pancreatic cancer patients and patients
with chronic pancreatitis, with sequences that were methylated
in chronic pancreatitis but unmethylated in pancreatic cancer
contributing to the specificity of the biomarker (Liggett et al.,
2010).
Ovarian Cancer
Symptoms of ovarian cancer are vague and non-specific, leading
to late diagnosis which in turn results in high patient mortality.
Several large scale efforts have been undertaken to determine the
efficacy of ovarian cancer screening using different configura-
tions of CA125 measurement and ultrasound imaging, includ-
ing the US PLCO Cancer Screening Study (Buys et al., 2011)
and the UKCTOCS study (Menon et al., 2009). However, to
date, these screening practices have not shown an improve-
ment in mortality (reviewed in Menon et al., 2014). There is
scope for improvement in the biomarkers used to detect ovar-
ian cancer. CA125, one of the cornerstones of ovarian cancer
screening trials, was first reported as being elevated in ovarian
cancer over 30 years ago (Bast et al., 1983), that is, even before
the invention of PCR. Since that time, molecular biology has
been transformed beyond recognition, and it seems reasonable
to hope that new techniques, vastly more powerful than any-
thing envisaged 3 decades ago, will enable the identification of
biomarkers that improve on the sensitivity and specificity of
CA125.
While many studies have reported aberrent methylation in
ovarian cancer (reviewed in Gloss and Samimi, 2014), there
are relatively few reports of ovarian cancer plasma methylation
biomarkers. Ibanez De Caceres et al. (2004) found methylation
of RASSF1A and BRCA1 promoters in plasma or serum in 25/50
(50%) and 9/50 (18%) of ovarian cancer samples, respectively,
with neither promoter methylated in any of 20 controls. The
number of negative control samples was insufficient to allow
precise conclusions about specificity, while other studies have
found both RASSF1A and BRCA1 to be methylated in small num-
bers of controls (Belinsky et al., 2005; Hsu et al., 2007; Radpour
et al., 2011; Zhang et al., 2011); however, assay differences make
direct comparison across these studies difficult. The MethDet56
method described above has been applied to ovarian cancer,
and several genes were found informative in identifying ovar-
ian cancer samples (Melnikov et al., 2009a; Liggett et al., 2011).
In a cohort of 30 patients with ovarian cancer, 30 patients with
benign ovarian disease and 30 healthy controls, methylation of
RASSF1A, CACLA, and EP300 combined differentiated between
patients with ovarian cancer and healthy controls with 90% sen-
sitivity and 87% specificity, while methylation of RASSF1A and
PGR differentiated between patients with ovarian cancer and
patients with benign ovarian disease with 80.0% sensitivity and
73.3% specificity (Liggett et al., 2011).
Because ovarian cancer is relatively rare, and diagnosed late,
plasma samples from early stage cases that could be used to
validate useful biomarker(s) are rare. Serum for CA125 mea-
surement is usually collected from ovarian cancer patients on
diagnosis, and hence serum is more often readily available for
biomarker studies in ovarian cancer. A number of studies iden-
tifying serum methylation ovarian cancer biomarkers have been
published (Dong et al., 2012; Zhang et al., 2013; Zhou et al., 2014),
however, a detailed description of these is beyond the scope of
this review.
Challenges in Working with Methylated
circDNA
Methylated circDNA presents a challenging substrate to work
with, largely because circDNA is dilute, with concentrations as
low as < 10 ng per mL of plasma in healthy subjects (El Mes-
saoudi et al., 2013; Warton et al., 2014). The methylated compo-
nent is an even smaller subfraction of this amount. Thus, many
of the technical issues relate simply to limited quantities of start-
ing material, a common problem for researchers working with
clinical samples. This can be partly addressed through the devel-
opment of DNApurificationmethods which accommodate larger
volumes of plasma input (Keeley et al., 2013; Warton et al., 2014);
however, care needs to be taken that this doesn’t compound
problems stemming from blood-derived PCR inhibitors (Grutz-
mann et al., 2008; Schrader et al., 2012). Fortunately, even for low
volumes of plasma starting material, ongoing technical develop-
ments mean that it is possible to analyze ever smaller amounts
of DNA.
As noted above, the size of early stage tumors may limit the
amount of DNA that is shed into the blood. However, there
are many unknown parameters in estimating how much DNA
a tumor is likely to release into the blood stream, starting from
the number of cells per cubic centimeter of tumor tissue, which
has been postulated to range from 1 × 108 to 1 × 109 per cm3
depending on tumor cell size and the proportion of stromal com-
ponents (Del Monte, 2009), to the rate and mechanism of DNA
release, both of which very little is known about at this stage. A
1 cm diameter tumor, containing about half a billion cells, with
only 0.01% genome equivalents in the circulation would present
as 17–20 tumor genomes, or 34–40 copies of a given sequence
per mL of plasma, assuming average human plasma volume to be
3 L for men and 2.5 L for women. With reported optimal lim-
its of methylation detection being 1–2 copies of DNA sequence
per assay (Pedersen et al., 2014), and with the option of detecting
targets concentrated from several mL of plasma in a single multi-
plexed assay once issues of blood-derived inhibitors are resolved,
it is conceivable that methylated DNA from tumors small enough
to be surgically removed could be detected. However, for assays
that detect target molecules with this very high sensitivity to be
effective, it is important that the chosen targets are not methy-
lated even at low levels in control blood samples, as the specificity
of the test would be compromised.
Another challenge in circDNA studies is that circDNA is frag-
mented. Most of the DNA present in plasma occurs as fragments
around 180 bases and 360 bases in size. This corresponds to the
smallest two bands of the apoptotic DNA ladder, and reflects the
likely apoptotic origin of the DNA (Jahr et al., 2001). A technical
consequence of this is that DNA purification methods that per-
form well for intact genomic DNA are not efficient at extracting
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circDNA (Devonshire et al., 2014), leading to further DNA losses
(and also inconsistencies in circDNA concentrations measured
by different labs).
The collection and processing of clinical samples for the dis-
covery and validation of plasma biomarkers also needs to be
carefully considered. Blood in EDTA tubes can only be stored
for a limited amount of time before leukocytes begin to lyse and
contribute their DNA to the plasma DNA fraction (Jung et al.,
2003; El Messaoudi et al., 2013; Warton et al., 2014). At the
very least, same day processing of blood samples is required so
that the circDNA does not become contaminated with genomic
leukocyte DNA. In clinical settings where patient samples are
collected one at a time, sample collection and processing can
become a major enterprise. Furthermore, determining the speci-
ficity of a biomarker, that is, its ability to correctly identify
negative samples, requires large numbers of cancer-free con-
trols, ideally age-matched and collected within the same setting
and in the same way as the cases. If control samples are col-
lected at different centers than the cancer samples, standard-
ized protocols are required so that variations in sample handling
between centers do not introduce artifacts (Gormally et al., 2004).
Problems can also arise from discovery and validation strate-
gies that compare samples from patients with cancer to sam-
ples from healthy individuals, insofar as in addition to cancer
specific biomarkers, the patient samples are also likely to show
changes due simply to the presence of inflammation. The result-
ing biomarker may not be able to differentiate between cancer
and other less serious conditions with an inflammation compo-
nent. These considerations are not specific to methylated DNA
biomarkers and apply to biomarker discovery and validation
generally.
Developing a diagnostic test for rare cancers such as pan-
creatic or ovarian cancer is more technically difficult than
developing a test for common cancers such as breast and col-
orectal cancer. This is because the assay adopted for rare can-
cers must have an extremely low false positive rate if the
test is to be clinically useful. A 100% sensitive test with 95%
specificity (i.e., 5% false positive rate), if targeted at colorec-
tal cancer, would return on average 1 correct cancer diagno-
sis and 8 false positive results after screening 160 patients,
whereas the same test applied to ovarian cancer screening would
return on average 1 correctly identified ovarian cancer diagno-
sis and 125 false positive results after screening 2500 patients,
assuming the prevalence of colorectal and ovarian cancer in
the screened population to be ∼1/160 and ∼1/2500, respec-
tively (Rauh-Hain et al., 2011; Church et al., 2014). Further-
more, colorectal and breast cancer are located at sites where a
confirmatory diagnosis can be obtained by the relatively non-
invasive procedures of colonoscopy and fine needle biopsy,
respectively, whereas pancreatic cancer and ovarian cancer can
require surgery for a final diagnosis to be made, thus a false
positive test result has much more serious consequences for
patients. The problems associated with a requirement for very
high sensitivity can be to some extent overcome by targeting the
screening test to at-risk populations with higher prevalence of
the cancer, e.g., BRCA1/2 mutation carriers for ovarian cancer
screening.
Future Directions
Technology has been evolving rapidly and much of the progress
in molecular biology involves techniques that can be directly
applied to DNA biomarker discovery and validation. Firstly, at
the discovery stage, it has become possible to interrogate ever
greater portions of the genome. From studies of one or several
candidate promoters, to microarrays that measure methylation
first at tens of thousands (Hill et al., 2011), then at hundreds of
thousands (Pan et al., 2012) of CpG sites, and finally to whole
genome sequencing that can be applied to bisulphite converted
DNA (Hovestadt et al., 2014) or to the captured methylated frac-
tion of a DNA sample (Nair et al., 2011; Warton et al., 2014),
the scope to identify differentially methylated regions is increas-
ing. The broader choice of candidates makes it more likely that
a biomarker, or panel of biomarkers, will be found that is well
able to differentiate between controls and cancer patient samples.
For rare cancers, it is particularly important that the biomarker(s)
are not methylated in cancer-free individuals. While past stud-
ies have often undertaken biomarker discovery by comparing
tumors with healthy adjacent matched tissue, the methylation
state of the healthy tissue of origin is not strictly speaking rele-
vant as a negative control if the healthy tissue does not contribute
DNA to the circDNA pool. A more appropriate negative control
is the leukocyte population, since these are the most likely source
of circDNA (Lui et al., 2002), and leukocytes have been included
as negative controls in discovery studies that successfully trans-
lated to clinical biomarkers, e.g., SEPT9 (Lofton-Day et al., 2008).
Another option is to use plasma directly as the discovery sub-
strate, with methylation of identified sequences then confirmed
in corresponding tumor tissue. The advantage of this approach is
that all the sources of circDNA in healthy individuals need not be
identified in order for them to be included in the negative con-
trol, since if a tissue type contributes DNA to the circDNA pool,
then it will be present in the tested samples. A limitation to this
approach is that while the tiny amounts of circDNA in plasma can
be effectively interrogated in a diagnostic assay based on PCR,
they do not lend themselves to genome-wide discovery strate-
gies that typically require larger starting inputs of DNA; however,
ongoing technical improvements are likely to overcome this.
At the individual sequence level, the capacity to measure
methylation is improving in sensitivity. For example, both con-
ventional and quantitative methylation-specific PCR require that
the methylated sequence is detected in a background, usually an
excess, of the related unmethylated sequence. Digital PCR, in
which the sample is diluted and partitioned into thousands or
millions of microdroplets, amplifies and detects a single target
sequence in a nanoliter reaction volume, helping to reduce com-
petition from the non-specific product (Day et al., 2013). Another
approach to eliminating competition from related sequences is to
carry out the PCR on solid phase media such as polyacrylamide
gel, and directly count the PCR-generated molecular colonies,
each corresponding to a single starting molecule of target DNA
(Chetverin and Chetverina, 2008). These emerging techniques
may improve the sensitivity of PCR-based methylation assays,
allowing biomarker detection in samples with less tumor DNA
than is currently possible.
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Experience with studies conducted to date is leading to a
better appreciation of the importance of sample handling and
pre-analytical processing (Gormally et al., 2004; El Messaoudi
et al., 2013). Unfortunately, the blood fractionation and circDNA
extraction steps are not always described in detail in published
studies, which makes comparison and interpretation of results
obtained by different labs difficult. Changes to sample processing
based on a better understanding of the biology of circDNA may
also help to improve yield. Studies from the Laktionov lab have
consistently reported two pools of extracellular DNA in blood,
the circDNA in plasma, and a cell surface-bound pool, which is
considerably more abundant than the plasma pool (Tamkovich
et al., 2008; Ponomaryova et al., 2011). The differences between
these two pools of DNA need to be further clarified (Rykova
et al., 2012), and any improvements in purified DNA yield would
be of great benefit to the field. Another pool of cell-free plasma
DNA is contained in blood exosomes, which have recently been
shown to contain double-stranded DNA in addition to mRNAs
and microRNAs (Thakur et al., 2014). In patients with cancer,
microsomal DNA includes DNA that is derived from the tumor
(Thakur et al., 2014), and hence may also be targeted in circulat-
ing tumor DNAmethylation analysis. Finally, it is hoped that the
emergence of personalized medicine will also boost and improve
bio-banking procedures, with easier access to carefully collected
and annotated cohorts of patient and control clinical samples
expediting the retrospective validation step of cancer biomarker
discovery.
In conclusion, a circDNA methylation biomarker for colorec-
tal cancer is already in the clinic, andmanymore are under inves-
tigation. Technological developments, technical improvements,
and a better understanding of circDNA biology are likely to yield
targets and assays that improve on previous outcomes. There is
reason to believe that these may be able to reach the sensitivity
and specificity values necessary to translate into a patient sur-
vival benefit through improved detection and complete surgical
removal of early stage cancers.
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